The TAS120-101 trial

Update October 2019: This international Phase I/II trial for those patients who have FGF/FGFR gene abnormalities in their tumour, and for whom there are no other available therapies, closed to recruitment on 31 October, 2019.  Data is currently maturing and results are awaited.

For further details on the TAS120-101 trial, go to:
and and search for trial number: NCT02052778

Back to previous page